

## THERAVECTYS APPOINTS NEW EXECUTIVE TEAM

*Following the closing of a funding round, Theravectys appoints a new executive team to implement its strategic plan.*

**PARIS, MAY 2, 2017 – THERAVECTYS, a vaccine company that designs safe and efficient T-cell vaccines based on its proprietary lentiviral vector platform, is pleased to announce the nomination of Jean Chalopin as Chairman-CEO, François Vallet, as Deputy General Manager, Pierre Charneau, as Head of the Theravectys – Pasteur Institute Joint-Lab and Divya Babin as Senior VP, Business Development.**

Jean Chalopin is a seasoned creative entrepreneur and business man. As the Executive Chairman of Deltec International Group, a long-standing banking group, he has been instrumental to the negotiation, management, operation and successful exits of various funds and companies, especially in the biotechnology sector, in the US, Europe, Japan and China.

François Vallet (Ecole Polytechnique, PhD in physics) has been involved in the management of biotechs for 15 years, including the creation of Genewave (equipment for molecular diagnostics) which he led for 6 years. He also held the position of manager at Vaxon Biotech and MABLIFE.

Pierre Charneau, (PhD. in biology), is the lentiviral vector technology inventor and Theravectys founder. He is a world renowned scientist and as the Head of the Molecular Virology & Vaccinology Unit of the Pasteur Institute has been the leader in the cutting-edge developments derived from his discovery.

Divya Babin, (Ecole Polytechnique, M.Sc. Virology) was formerly in charge of building relations with Asia- and US-based companies on behalf of the research consortium GLOBAL CARE Initiative. She has international experience in developing research collaborations within the biotech industry.

“I am extremely proud to be leading this new team and implementing Theravectys’ portfolio strategy, says Jean Chalopin, CEO. “Our technology leverages 20+ years of research and benefits from the unfaltering dedication of pioneer technology founder Dr. Pierre Charneau.”

“Lentiviral Vectors vaccines are probably the biggest silent revolution in vaccination since the Pasteur vaccine against rabies,” he adds. “And we have in our hands the responsibility and the chance to bring this progress to the millions of patients awaiting it”.

### About THERAVECTYS

THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer technology inventor Dr. Pierre Charneau, as a spin-off of the [Pasteur Institute](#), Theravectys leverages its [proprietary platform](#) to deliver safe and efficient T-cell vaccines as a response to critical unmet medical needs. Our purpose: ‘profoundly transform global health’. Our approach: strategic industrial partnering for leading our [PoC-validated vaccine-candidates](#) to clinical trials and to market.

### For more information

+33 43 90 19 20

[contact@theravectys.com](mailto:contact@theravectys.com)

